Health Source: YJH-012 Injection Obtains Approval for Drug Clinical Trials.

HealthAnnouncement, the company's holding subsidiary Li Zhu Group has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, approving the clinical trial of YJH-12 injection. YJH-012 injection is a new siRNA drug jointly developed by Li Zhu Group and Youjia Biomedical Technology Co., Ltd., indicated for gout. As of the date of the announcement, the accumulated direct research and development expenses for YJH-12 injection are approximately RMB 25.7386 million. There are currently no nucleic acid products with the same indication on the domestic market.